查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1738671

流感病毒（H1N1）疫苗市場規模依疫苗類型、技術、年齡層、區域範圍和預測分類：

Global Influenza Virus Vaccine (H1N1) Market Size By Vaccine Type, By Technology, By Age Group, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

流感病毒（H1N1）疫苗市場規模及預測

2024 年流感病毒 (H1N1) 疫苗市場規模價值為 38 億美元，預計到 2032 年將達到 56.2 億美元，預測期內（2026-2032 年）的複合年成長率為 5.52%。

推動全球流感病毒（H1N1）疫苗市場發展的因素

流感病毒 (H1N1) 疫苗市場的市場促進因素可能受到多種因素的影響，其中包括：

  • 流感病例數上升：全球流感發生率上升是推動H1N1疫苗市場成長的主要因素。季節性流行病和大流行病導致的高發病率和高死亡率，推動了對有效疫苗的需求。
  • 政府疫苗宣傳活動和計畫：全球各地政府都在進行疫苗宣傳活動，以控制和避免流感疫情爆發。這些措施推動了市場需求，包括免費或高額補貼的疫苗接種項目以及公眾意識宣傳活動。
  • 免疫技術的進步：疫苗研發的進步，例如重組疫苗和細胞製造技術，正在提高疫苗生產的有效性和效率。這些發展正在推動疫苗覆蓋率和投資的增加。
  • 教育和公眾意識：隨著人們越來越意識到疫苗接種的好處和流感的風險，接種疫苗的人數也在增加。這需要政府和醫療機構的教育投入。
  • 人口老化：隨著全球老年人口的成長，對 H1N1併發症的需求也隨之增加，老年人成為流感疫苗接種宣傳活動的主要目標群體。
  • 醫療基礎建設：更完善的醫療基礎設施，尤其是在開發中國家，將使疫苗的分發和管理更有效率。醫療服務的普及和醫療設施的改善將有助於市場擴張。
  • 病毒的季節性變異：流感病毒的變異性使得疫苗接種必須每年更新，以確保對最新疫苗的需求穩定。季節性流感病毒的流行推動了復發性疫苗的分發和研發。

限制全球甲型H1N1流感疫苗市場的因素

多種因素可能對甲型H1N1流感疫苗市場造成限制和挑戰，包括：

  • 生產成本高：流感疫苗，尤其是H1N1流感疫苗，研發和生產成本高。這些成本包括臨床研究、生產製造、品管、研發等。高昂的生產成本可能會限制疫苗的可近性和可負擔性，尤其是在低收入社區。
  • 嚴格的監管要求：疫苗核准流程漫長而艱鉅。在獲準用於公眾使用之前，疫苗必須符合食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構制定的嚴格標準和要求。這可能會延遲新疫苗的上市。
  • 疫苗猶豫：低疫苗接種率可歸因於公眾對疫苗有效性和安全性的不信任和錯誤訊息。許多因素，包括文化觀念、社群媒體傳播的錯誤訊息以及既往疫苗接種經歷，都會影響疫苗猶豫。
  • 供應鏈挑戰：由於複雜的製造流程、複雜的低溫運輸物流、分銷問題等，維持穩定的疫苗供應具有挑戰性。供應鏈的任何中斷都可能影響疫苗供應的時間表。
  • 有效性有限：流感疫苗，尤其是大流行性流感疫苗的有效性，可能因疫苗株與流行病毒株的匹配程度而每年都有所不同。疫苗有效性的波動可能會影響公眾信任度和疫苗接種率。
  • 智慧財產權和專利問題：專利和智慧財產權可能會阻礙新市場的進入，抑制競爭和創新，並影響疫苗的取得和成本。
  • 資金限制：疫苗開發、研究和分發資金不足可能會阻礙市場擴張。這在資源匱乏的開發中國家尤其成問題。
  • 安全性和副作用擔憂：疫苗通常是安全的，但關於副作用的報告可能會影響大眾的接受度和認知。對疫苗安全性的擔憂可能會導致疫苗接種率下降，並阻礙市場擴張。
  • 政治和經濟因素：公共衛生宣傳活動、疫苗分發和疫苗生產都可能受到政治不穩定或景氣衰退的不利影響。預算削減和優先順序調整可能會導致免疫接種計畫的資金和支持減少。
  • 技術限制：疫苗製造技術不斷發展，但技術限制可能會對實現更快、更有效的免疫造成障礙。

目錄

第1章 引言

  • 市場定義
  • 市場區隔
  • 調查方法

第2章執行摘要

  • 主要發現
  • 市場概覽
  • 市場亮點

第3章市場概述

  • 市場規模和成長潛力
  • 市場趨勢
  • 市場促進因素
  • 市場限制
  • 市場機會
  • 波特五力分析

4. 甲型H1N1流感疫苗市場（依疫苗類型）

  • 去活化疫苗
  • 活病毒疫苗

5. 流感病毒（H1N1）疫苗市場（依技術）

  • 基於雞蛋的技術
  • 基於細胞的技術
  • 重組技術

6. 甲型H1N1流感疫苗市場（依年齡層）

  • 孩子們
  • 成人
  • 老年人

第7章區域分析

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 拉丁美洲
  • 巴西
  • 阿根廷
  • 智利
  • 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第8章市場動態

  • 市場促進因素
  • 市場限制
  • 市場機會
  • COVID-19 市場影響

第9章 競爭態勢

  • 主要企業
  • 市場佔有率分析

第10章 公司簡介

  • Butantan Institute
  • Denka Seiken Co Ltd
  • Green Cross Corp
  • Baxter International Inc.
  • CSL
  • Glaxosmithkline PLC
  • Hualan Biological Engineering Inc.
  • Novartis
  • Sinovac Biotech
  • Sanofi Pasteur

第11章 市場展望與機會

  • 新興技術
  • 未來市場趨勢
  • 投資機會

第12章 附錄

  • 簡稱列表
  • 來源和參考文獻
簡介目錄
Product Code: 35803

Influenza Virus Vaccine (H1N1) Market Size And Forecast

Influenza Virus Vaccine (H1N1) Market size was valued at USD 3.8 Billion in 2024 and is projected to reach USD 5.62 Billion by 2032, growing at a CAGR of 5.52% during the forecast period 2026-2032.

Global Influenza Virus Vaccine (H1N1) Market Drivers

The market drivers for the Influenza Virus Vaccine (H1N1) Market can be influenced by various factors. These may include:

  • A Rise in the Number of Influenza Cases: The global increase in influenza incidence is a major factor propelling the market for the H1N1 vaccination. High rates of morbidity and mortality brought on by seasonal outbreaks and pandemics raise the need for efficacious vaccinations.
  • Governmental Campaigns and Vaccine Programs: Worldwide, immunization campaigns are being carried out by governments in an effort to contain and avoid influenza outbreaks. These measures, which increase market demand, include immunization programs that are either free or heavily subsidized and public awareness campaigns.
  • Progress in Immunization Technology: The effectiveness and efficiency of vaccine manufacture have increased thanks to advancements in vaccine development, including recombinant vaccines and cell-based manufacturing techniques. These developments foster greater adoption rates and draw in more investments.
  • Education and Public Awareness: As people become more aware of the advantages of vaccination and the dangers of influenza, the number of people being vaccinated has increased. Government and healthcare groups' educational initiatives are vital to this.
  • Population Aging: The need for H1N1 vaccinations is driven by the growing senior population worldwide, who are more vulnerable to influenza complications. One important target group for influenza vaccination campaigns is older persons.
  • Development of Healthcare Infrastructure: Enhancements in the infrastructure of healthcare, especially in developing nations, enable more efficient distribution and administration of vaccinations. Access to medical services and improved healthcare facilities facilitate market expansion.
  • The Virus's Seasonal Variability: Annual vaccination updates are necessary due to the influenza virus's changing nature, which guarantees a steady demand for the newest vaccinations. The dissemination and development of recurrent vaccines are driven by seasonal flu viruses.

Global Influenza Virus Vaccine (H1N1) Market Restraints

Several factors can act as restraints or challenges for the Influenza Virus Vaccine (H1N1) Market. These may include:

  • High Production Costs: Developing and manufacturing influenza vaccines, especially those for H1N1, is expensive. These expenses cover clinical studies, manufacturing, quality control, and research & development. Particularly in low-income areas, high production costs may restrict the accessibility and affordability of vaccines.
  • Tight Regulatory Requirements: The approval process for vaccines is a laborious and time-consuming process. Before a vaccine is licensed for use in the general population, it must comply with strict standards and requirements set by regulatory authorities like the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This may cause a delay in the release of new vaccines.
  • Vaccine Hesitancy: Reduced vaccination rates may result from public mistrust and false information regarding the efficacy and safety of vaccines. A number of factors, including as cultural views, false information disseminated via social media, and prior vaccination experiences, all have an impact on vaccine hesitancy.
  • Supply Chain Difficulties: Keeping a steady supply of vaccinations in place can be difficult because of things like complicated manufacturing processes, complicated cold chain logistics, and problems with distribution. Any interruption to the supply chain may have an impact on when vaccines are available on time.
  • Limited Efficacy: Depending on how well the vaccine strains match the strains of the virus that is circulating, the efficacy of influenza vaccinations, particularly the H1N1, can change from year to year. Public trust and vaccination uptake may be impacted by variations in vaccine efficacy.
  • Intellectual Property and Patent Issues: Patents and intellectual property rights have the potential to impede competition and innovation by erecting obstacles in the way of new market entrants. This may also have an impact on vaccine accessibility and cost.
  • Financial Restraints: Inadequate funds for vaccine development, research, and distribution may prevent the market from expanding. This is especially problematic in developing nations with constrained financial resources.
  • Safety and Adverse Effects Concerns: Vaccines are typically safe, but public acceptance and perception may be impacted by stories of negative effects. Fears regarding the safety of vaccines may cause vaccination rates to decline and hinder market expansion.
  • Political and Economic Factors: Public health campaigns, vaccine distribution, and vaccine manufacture can all be adversely affected by political unrest and economic downturns. Programs for immunization may receive less money and support as a result of budget cuts and rearranged priorities.
  • Technological Restrictions: Vaccine production technology is continuously developing. But there may be obstacles in the way of creating vaccinations that are both faster to produce and more effective due to existing technological restrictions.

Global Influenza Virus Vaccine (H1N1) Market Segmentation Analysis

The Global Influenza Virus Vaccine (H1N1) Market is Segmented on the basis of Vaccine Type, Technology, Age Group, and Geography.

Influenza Virus Vaccine (H1N1) Market, By Vaccine Type

  • Inactivated Vaccines: These vaccines contain killed viruses and are typically administered via injection.
  • Live Attenuated Vaccines: These contain weakened live viruses and are usually administered through nasal sprays.

Influenza Virus Vaccine (H1N1) Market, By Technology

  • Egg-Based Technology: Traditional method involving the growth of the virus in chicken eggs.
  • Cell-Based Technology: Uses cultured mammalian cells for virus growth.
  • Recombinant Technology: Involves the use of recombinant DNA technology to produce vaccines.

Influenza Virus Vaccine (H1N1) Market, By Age Group

  • Pediatric: Vaccines specifically formulated for children.
  • Adults: Standard doses for the general adult population.
  • Elderly: High-dose or adjuvanted vaccines for individuals over 65 years.
  • Influenza Virus Vaccine (H1N1) Market, Geography
  • North America: Market conditions and demand in the United States, Canada, and Mexico.
  • Europe: Analysis of the Influenza Virus Vaccine (H1N1) Market in European countries.
  • Asia-Pacific: Focusing on countries like China, India, Japan, South Korea, and others.
  • Middle East and Africa: Examining market dynamics in the Middle East and African regions.
  • Latin America: Covering market trends and developments in countries across Latin America.

Key Players

  • Butantan Institute
  • Denka Seiken Co Ltd
  • Green Cross Corp
  • Baxter International Inc.
  • CSL
  • Glaxosmithkline PLC
  • Hualan Biological Engineering Inc.
  • Novartis
  • Sinovac Biotech
  • Sanofi Pasteur

TABLE OF CONTENTS

1. Introduction

  • Market Definition
  • Market Segmentation
  • Research Methodology

2. Executive Summary

  • Key Findings
  • Market Overview
  • Market Highlights

3. Market Overview

  • Market Size and Growth Potential
  • Market Trends
  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Porter's Five Forces Analysis

4. Influenza Virus Vaccine (H1N1) Market, By Vaccine Type

  • Inactivated Vaccines
  • Live Attenuated Vaccines

5. Influenza Virus Vaccine (H1N1) Market, By Technology

  • Egg-Based Technology
  • Cell-Based Technology
  • Recombinant Technology

6. Influenza Virus Vaccine (H1N1) Market, By Age Group

  • Pediatric
  • Adults
  • Elderly

7. Regional Analysis

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Latin America
  • Brazil
  • Argentina
  • Chile
  • Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

8. Market Dynamics

  • Market Drivers
  • Market Restraints
  • Market Opportunities
  • Impact of COVID-19 on the Market

9. Competitive Landscape

  • Key Players
  • Market Share Analysis

10. Company Profiles

  • Butantan Institute
  • Denka Seiken Co Ltd
  • Green Cross Corp
  • Baxter International Inc.
  • CSL
  • Glaxosmithkline PLC
  • Hualan Biological Engineering Inc.
  • Novartis
  • Sinovac Biotech
  • Sanofi Pasteur

11. Market Outlook and Opportunities

  • Emerging Technologies
  • Future Market Trends
  • Investment Opportunities

12. Appendix

  • List of Abbreviations
  • Sources and References